GleamWall
中文EN

HOWL Werewolf Therapeutics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1785530 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY61.4%
TTM EPS YoY63.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-154.6%
ROA-46.0%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets84.2%
Debt / equity0.00x
Current ratio1.19x
Interest coverage-7.97x

Cash quality & payout

Operating cash flow / net income0.85x
Accruals ratio-6.8%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue—————
R&D expense$44.83M$56.43M$41.78M$53.76M$35.27M
SG&A expense$15.85M$19.05M$18.67M$18.70M$14.82M
Operating income-$60.68M-$73.59M-$40.50M-$56.06M-$50.09M
Interest expense$5.27M$4.66M$3.14M$0—
Income tax$0————
Net income-$60.82M-$70.52M-$37.37M-$53.81M-$49.98M
EBITDA-$59.04M-$71.78M-$38.74M-$54.95M-$49.87M
EPS (basic)-1.32-1.63-1.05-1.86-10.94
EPS (diluted)-1.33-1.63-1.05-1.86-10.94
Weighted avg. shares (diluted)46.81M43.86M35.65M28.86M18.45M
Balance sheet
Cash & equivalents$57.05M$112.22M$155.58M$130.53M$158.83M
Current assets$58.59M$113.07M$138.37M$140.20M$161.07M
PP&E, net$4.69M$6.32M$7.96M$8.99M$2.91M
Total assets$69.40M$126.93M$174.83M$160.25M$179.25M
Current liabilities$36.15M$15.18M$19.38M$23.99M$11.87M
Long-term debt$32.09M$32.09M$40.00M——
Total debt$32.09M$32.09M$40.00M——
Total liabilities$44.59M$53.54M$63.46M$37.91M$26.46M
Shareholders' equity$24.80M$73.39M$111.37M$122.34M$152.79M
Net debt-$24.96M-$80.13M-$115.58M——
Shares outstanding48.60M44.83M39.11M31.43M27.31M
Cash flow statement
Operating cash flow-$60.29M-$56.19M-$32.61M-$40.60M-$42.88M
Capital expenditure$0$254,000$769,000$3.61M$498,000
Free cash flow-$60.29M-$56.44M-$33.38M-$44.21M-$43.37M
Investing cash flow$0-$254,000-$769,000-$3.61M-$498,000
Financing cash flow$6.03M$13.08M$58.43M$15.91M$109.43M
Depreciation & amortization$1.63M$1.81M$1.76M$1.10M$216,000
Stock-based compensation$6.25M$8.83M$8.01M$7.40M$4.09M

Free plan shows the latest 5 periods; Pro shows all 6 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.